Levels of Beta-microseminoprotein in Blood and Risk of Prostate Cancer in Multiple Populations

Overview

Journal J Natl Cancer Inst

Publisher Oxford University Press

Specialty Oncology

Date 2012 Dec 6

PMID 23213189

Citations 25

Authors

Christopher A Haiman

Daniel O Stram

Andrew J Vickers

Lynne R Wilkens

Katharina Braun

Camilla Valtonen-Andre

Mari Peltola

Kim Pettersson

Kevin M Waters

Loic Le Marchand

Laurence N Kolonel

Brian E Henderson

Hans Lilja

Affiliations

Soon will be listed here.

Abstract

Background: A common genetic variant (rs10993994) in the 5' region of the gene encoding β-microseminoprotein (MSP) is associated with circulating levels of MSP and prostate cancer risk. Whether MSP levels are predictive of prostate cancer risk has not been evaluated.

Methods: We investigated the prospective relationship between circulating plasma levels of MSP and prostate cancer risk in a nested case-control study of 1503 case subjects and 1503 control subjects among black, Latino, Japanese, Native Hawaiian, and white men from the Multiethnic Cohort study. We also examined the ability of MSP to serve as a biomarker for discriminating prostate cancer case subjects from control subjects. All statistical tests are two-sided.

Results: In all racial and ethnic groups, men with lower MSP levels were at greater risk of developing prostate cancer (odds ratio = 1.02 per one unit decrease in MSP, P < .001 in the prostate-specific antigen [PSA]-adjusted analysis). Compared with men in the highest decile of MSP, the multivariable PSA-adjusted odds ratio was 3.64 (95% confidence interval = 2.41 to 5.49) for men in the lowest decile. The positive association with lower MSP levels was observed consistently across racial and ethnic populations, by disease stage and Gleason score, for men with both high and low levels of PSA and across all genotype classes of rs10993994. However, we did not detect strong evidence of MSP levels in improving prostate cancer prediction beyond that of PSA.

Conclusions: Regardless of race and ethnicity or rs10993994 genotype, men with low blood levels of MSP have increased risk of prostate cancer.

Citing Articles

Identifying proteomic risk factors for overall, aggressive and early onset prostate cancer using Mendelian randomization and tumor spatial transcriptomics.

Desai T, Hedman A, Dimitriou M, Koprulu M, Figiel S, Yin W medRxiv. 2023; .

PMID: 37790472 PMC: 10543057. DOI: 10.1101/2023.09.21.23295864.

Development of a novel, clinically relevant anoikis-related gene signature to forecast prognosis in patients with prostate cancer.

Liu X, Wang K Front Genet. 2023; 14:1166668.

PMID: 37719710 PMC: 10499615. DOI: 10.3389/fgene.2023.1166668.

Identification of blood protein biomarkers associated with prostate cancer risk using genetic prediction models: analysis of over 140,000 subjects.

Zhong H, Zhu J, Liu S, Ghoneim D, Surendran P, Liu T Hum Mol Genet. 2023; 32(22):3181-3193.

PMID: 37622920 PMC: 10630250. DOI: 10.1093/hmg/ddad139.

An atlas of genetic scores to predict multi-omic traits.

Xu Y, Ritchie S, Liang Y, Timmers P, Pietzner M, Lannelongue L Nature. 2023; 616(7955):123-131.

PMID: 36991119 PMC: 10323211. DOI: 10.1038/s41586-023-05844-9.

Suggesting Tissue-Specific MSMB Gene Promoter as a Novel Approach for Prostate Targeted Gene Therapy.

Darayee M, Geramizadeh B, Tabei S, Rezvani A, Soleimanian S, Rahimi A Asian Pac J Cancer Prev. 2022; 23(6):1993-2000.

PMID: 35763641 PMC: 9587823. DOI: 10.31557/APJCP.2022.23.6.1993.

References

Xu X, Valtonen-Andre C, Savblom C, Hallden C, Lilja H, Klein R . Polymorphisms at the Microseminoprotein-beta locus associated with physiologic variation in beta-microseminoprotein and prostate-specific antigen levels. Cancer Epidemiol Biomarkers Prev. 2010; 19(8):2035-42. PMC: 2946372. DOI: 10.1158/1055-9965.EPI-10-0431. View

Gudmundsson J, Sulem P, Gudbjartsson D, Blondal T, Gylfason A, Agnarsson B . Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat Genet. 2009; 41(10):1122-6. PMC: 3562712. DOI: 10.1038/ng.448. View

Abrahamsson P, Lilja H, Falkmer S, WADSTROM L . Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands. Prostate. 1988; 12(1):39-46. DOI: 10.1002/pros.2990120106. View

Thomas G, Jacobs K, Yeager M, Kraft P, Wacholder S, Orr N . Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet. 2008; 40(3):310-5. DOI: 10.1038/ng.91. View

Bjartell A, Al-Ahmadie H, Serio A, Eastham J, Eggener S, Fine S . Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy. Clin Cancer Res. 2007; 13(14):4130-8. PMC: 2660867. DOI: 10.1158/1078-0432.CCR-06-3031. View

Lilja H, Cronin A, Dahlin A, Manjer J, Nilsson P, Eastham J . Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer. 2010; 117(6):1210-9. PMC: 3412541. DOI: 10.1002/cncr.25568. View

Waters K, Stram D, Le Marchand L, Klein R, Valtonen-Andre C, Peltola M . A common prostate cancer risk variant 5' of microseminoprotein-beta (MSMB) is a strong predictor of circulating beta-microseminoprotein (MSP) levels in multiple populations. Cancer Epidemiol Biomarkers Prev. 2010; 19(10):2639-46. PMC: 3041671. DOI: 10.1158/1055-9965.EPI-10-0427. View

Whitaker H, Warren A, Eeles R, Kote-Jarai Z, Neal D . The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target. Prostate. 2009; 70(3):333-40. DOI: 10.1002/pros.21059. View

Eeles R, Kote-Jarai Z, Olama A, Giles G, Guy M, Severi G . Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet. 2009; 41(10):1116-21. PMC: 2846760. DOI: 10.1038/ng.450. View

10.

Shukeir N, Arakelian A, Kadhim S, Garde S, Rabbani S . Prostate secretory protein PSP-94 decreases tumor growth and hypercalcemia of malignancy in a syngenic in vivo model of prostate cancer. Cancer Res. 2003; 63(9):2072-8. View

11.

Whitaker H, Kote-Jarai Z, Ross-Adams H, Warren A, Burge J, George A . The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine. PLoS One. 2010; 5(10):e13363. PMC: 2954177. DOI: 10.1371/journal.pone.0013363. View

12.

Haiman C, Chen G, Blot W, Strom S, Berndt S, Kittles R . Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans. PLoS Genet. 2011; 7(5):e1001387. PMC: 3102736. DOI: 10.1371/journal.pgen.1001387. View

13.

Mitrunen K, Pettersson K, Piironen T, Bjork T, Lilja H, Lovgren T . Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin Chem. 1995; 41(8 Pt 1):1115-20. View

14.

Reeves J, Dulude H, Panchal C, Daigneault L, Ramnani D . Prognostic value of prostate secretory protein of 94 amino acids and its binding protein after radical prostatectomy. Clin Cancer Res. 2006; 12(20 Pt 1):6018-22. DOI: 10.1158/1078-0432.CCR-06-0625. View

15.

Lundwall A, Lilja H . Molecular cloning of human prostate specific antigen cDNA. FEBS Lett. 1987; 214(2):317-22. DOI: 10.1016/0014-5793(87)80078-9. View

16.

Kote-Jarai Z, Olama A, Giles G, Severi G, Schleutker J, Weischer M . Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet. 2011; 43(8):785-91. PMC: 3396006. DOI: 10.1038/ng.882. View

17.

Ulvsback M, Lindstrom C, Weiber H, Abrahamsson P, Lilja H, Lundwall A . Molecular cloning of a small prostate protein, known as beta-microsemenoprotein, PSP94 or beta-inhibin, and demonstration of transcripts in non-genital tissues. Biochem Biophys Res Commun. 1989; 164(3):1310-5. DOI: 10.1016/0006-291x(89)91812-3. View

18.

Vaisanen V, Peltola M, Lilja H, Nurmi M, Pettersson K . Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments. Anal Chem. 2006; 78(22):7809-15. DOI: 10.1021/ac061201+. View

19.

Guo M, Teng M, Niu L, Liu Q, Huang Q, Hao Q . Crystal structure of the cysteine-rich secretory protein stecrisp reveals that the cysteine-rich domain has a K+ channel inhibitor-like fold. J Biol Chem. 2004; 280(13):12405-12. DOI: 10.1074/jbc.M413566200. View

20.

Vickers A, Cronin A, Bjork T, Manjer J, Nilsson P, Dahlin A . Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ. 2010; 341:c4521. PMC: 2939950. DOI: 10.1136/bmj.c4521. View